The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-01 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

By Nuijten Mark J.C.   Aultman Rick   Carpeño Javier de Castro   Vergnenègre Alain   Chouaid Christos   Walzer Stefan   Siebert Uwe  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2193-2201

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic Study of Weekly (Days 1-5) Low-dose S-1 in Patients with Non-Small-Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 2, 2012-05 ,pp. : 167-172

Bentham Science Publishers

Access to resources Recommend Favorite

Dose Escalation Study of Paclitaxel in Combination with Fixed-Dose Irinotecan in Patients with Advanced Non-Small Cell Lung Cancer (JCOG 9807)

By  

Oncology, Vol. 66, Iss. 2, 2004-05 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 82, Iss. 1, 2012-01 ,pp. : 25-29

Karger

Access to resources Recommend Favorite